Where can researchers source third-party tested KPV?

Midwest Peptide supplies research-grade KPV with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

KPV Research: Anti-Inflammatory Peptide | Midwest Peptide

CJC-1295 and Ipamorelin: A Research Review of Growth Hormone Releasing Peptide CombinationsPrev|TB-500 Research: Reviewing the Thymosin Beta-4 Fragment LiteratureNext

KPV Peptide Research: The Anti-Inflammatory Tripeptide and Its Preclinical Literature

KLOW Blend · Published April 8, 2026 · Updated May 18, 2026 · 9 min read

Quick Answer

KPV is the anti-inflammatory C-terminal tripeptide of alpha-MSH studied in research for receptor-independent anti-inflammatory activity through PEPT1 transporter uptake. Studies examine cytokine modulation, NF-kB suppression, and dermal and intestinal inflammation biomarkers across cellular and rodent research models. For research use only, not for human consumption.

KPV Peptide Research: The Anti-Inflammatory Tripeptide and Its Preclinical Literature

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

What Is KPV?
KPV and the Anti-Inflammatory Literature
The PEPT1 Transporter and Cellular Uptake
KPV in Intestinal Inflammation Research
KPV in Dermal Research
KPV in the KLOW Blend
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

KPV peptide research has produced a focused but conceptually rich body of preclinical literature on small anti-inflammatory peptides derived from melanocortin biology. As the anti-inflammatory tripeptide component of the KLOW peptide blend, KPV brings the research base of the alpha-MSH C-terminal fragment to the formulation. This article reviews the published literature on KPV, with a focus on its origin as the C-terminal tripeptide of alpha-MSH, its anti-inflammatory activity in research models, the proposed mechanism of cellular uptake through the PEPT1 transporter, and the dermal and intestinal research contexts where KPV has been most extensively studied.

Frequently Asked Questions

What is KPV in research contexts?

KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminal sequence of alpha-MSH. It is studied in preclinical research for anti-inflammatory effects, PEPT1 transporter uptake, and dermal and intestinal repair models.

What is KPV and how does it work?

KPV is the C-terminal tripeptide of alpha-MSH (lysine-proline-valine), demonstrating anti-inflammatory activity through NF-kB pathway modulation and intestinal uptake via the PEPT1 transporter, making it useful in dermal and intestinal inflammation research.

What KPV research applications inform its role in KLOW?

KPV research demonstrates anti-inflammatory effects in colitis models, dermal inflammation, and asthma research. These findings support its inclusion in KLOW for the anti-inflammatory dimension of tissue repair, complementing structural repair from the other peptides.

Is KPV approved for human use?

No. KPV is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Glossary

Key terms used in this article.

Alpha-MSH: Alpha-melanocyte-stimulating hormone, a 13-amino-acid neuropeptide derived from POMC; KPV is its C-terminal tripeptide.
PEPT1: An intestinal di- and tripeptide transporter that facilitates oral uptake of small peptides including KPV.
NF-kB: Nuclear factor kappa B, a transcription factor central to inflammatory gene expression that is modulated by KPV.
Multi-Peptide Blend: A research formulation combining two or more peptides to study additive or synergistic biological effects.
KPV: A tripeptide (lysine-proline-valine) corresponding to the C-terminal of alpha-MSH, studied for anti-inflammatory effects.
Tissue Repair: The biological process restoring damaged tissue through inflammation, proliferation, and remodeling.
Anti-Inflammatory: Reducing inflammation by modulating cytokine signaling, immune cell activity, or downstream inflammatory mediators.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. KPV is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of a formal research protocol.

What Is KPV?

KPV is a tripeptide composed of three amino acids: lysine, proline, and valine. The name itself is the single letter amino acid code for these three residues. KPV corresponds to the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH), a 13 amino acid neuropeptide that is part of the broader melanocortin family. The full alpha-MSH peptide has been studied for decades for its activity at melanocortin receptors, its role in pigmentation biology, and its anti-inflammatory effects observed in research models.

The research interest in KPV emerged from observations that the C-terminal fragment of alpha-MSH retained anti-inflammatory activity even when separated from the rest of the parent peptide. Investigators studying which portion of alpha-MSH was responsible for its anti-inflammatory effects identified the C-terminal tripeptide as a key active fragment, and KPV has since been studied as a research tool in its own right. The discovery was important because it suggested that a small, stable tripeptide could be used to study anti-inflammatory pathways without the broader receptor activation profile of the full alpha-MSH molecule.

The chemical simplicity of KPV is one of its defining features as a research tool. It is much smaller than most peptides studied in research settings, which has implications for its stability, its cellular uptake, and the methods researchers use to handle it in laboratory experiments. The small size also makes KPV chemically tractable for synthesis and characterization, supporting its use in standardized preclinical research.

KPV and the Anti-Inflammatory Literature

The most studied feature of KPV in published preclinical research is its anti-inflammatory activity. Research models have used KPV in cultured cells and in animal models to examine its effects on inflammatory cytokine production, immune cell activation, and the broader inflammatory response in tissues. The general pattern in the literature is that KPV administration is associated with reductions in markers of inflammation in research models, with the specific endpoints varying across study designs.

Cytokine measurements are one of the most common endpoints in KPV research. Studies have examined KPV effects on the production of inflammatory cytokines such as tumor necrosis factor alpha, interleukin 6, and interleukin 8 in cultured cells exposed to inflammatory stimuli. The published findings generally support the idea that KPV can dampen the production of these inflammatory mediators in research models, although the magnitude and specificity of the effect depend on experimental conditions.

Cell culture work on KPV has used a range of immune and structural cell types, including macrophages, intestinal epithelial cells, keratinocytes, and other models relevant to dermal and mucosal biology. Across these systems, the research findings on KPV anti-inflammatory activity have been largely consistent, providing an experimental foundation for the broader interest in KPV as a research tool.

The PEPT1 Transporter and Cellular Uptake

A particularly interesting feature of KPV in research is the proposed mechanism by which it enters cells. Most peptides cannot freely cross the cell membrane, and their cellular activity depends on either binding to extracellular receptors or being taken up through specific transport mechanisms. KPV has been studied for its uptake through the PEPT1 oligopeptide transporter, which is expressed on intestinal epithelial cells and on several other cell types involved in research models.

The PEPT1 transporter normally moves di- and tripeptides across cell membranes as part of the absorption of small peptide nutrients in the gastrointestinal tract. Research on KPV has identified this transporter as a route by which the tripeptide can enter cells and exert intracellular anti-inflammatory effects. This proposed mechanism is significant because it provides a transporter-mediated cellular entry pathway that does not depend on classical melanocortin receptor binding, expanding the conceptual scope of how small peptides derived from alpha-MSH can produce biological effects in research models.

The melanocortin receptor independence of KPV anti-inflammatory activity has been one of the more discussed features of the published literature. Researchers have used melanocortin receptor knockout models and pharmacological blockade of melanocortin receptors to test whether KPV effects depend on these classical receptors. The findings generally support a melanocortin-independent mechanism, which has positioned KPV as a tool for studying anti-inflammatory pathways that operate through cellular uptake and intracellular targets rather than through cell surface receptor activation.

KPV in Intestinal Inflammation Research

The intestinal research literature is one of the most active areas of KPV preclinical investigation, in part because PEPT1 is highly expressed in intestinal epithelial cells. Rodent models of intestinal inflammation have been used to evaluate KPV effects on histological measures of inflammation, cytokine expression in intestinal tissue, and broader markers of mucosal health.

Published research on KPV in intestinal inflammation models has examined endpoints relevant to inflammatory bowel disease research in preclinical settings. Studies have used standardized rodent inflammation protocols to examine whether KPV administration affects the severity and duration of inflammation in research models, with the findings generally supporting an anti-inflammatory effect that is consistent with the broader cell culture literature.

The intestinal research context is important for KPV because it ties the proposed PEPT1-mediated uptake mechanism directly to a tissue where the transporter is highly expressed. This convergence of mechanism and target tissue has made the intestinal research literature one of the more conceptually clean parts of the KPV preclinical evidence base.

KPV in Dermal Research

Dermal research is another active area of KPV preclinical investigation. Skin is a tissue where inflammation plays a central role in many research models, and KPV has been studied for its effects on dermal inflammation endpoints in cultured keratinocytes, in skin organ culture systems, and in rodent skin inflammation models.

The dermal research literature on KPV intersects with the broader literature on small peptides studied in skin biology, including GHK-Cu, the copper tripeptide that is also a constituent of the KLOW blend. The two peptides occupy different functional niches in dermal research. GHK-Cu is generally studied for its effects on fibroblast activity and extracellular matrix biology, while KPV is studied for its effects on inflammatory pathways in dermal cells. The combination of the two in research formulations like KLOW reflects the conceptual interest in studying dermal repair and dermal inflammation pathways together rather than in isolation.

Cell culture studies in keratinocytes have examined KPV effects on the production of inflammatory mediators and on the cellular response to inflammatory stimuli. Animal model studies have extended these findings to whole tissue contexts, providing additional preclinical evidence on KPV anti-inflammatory activity in dermal research.

KPV in the KLOW Blend

In the KLOW formulation, KPV provides the anti-inflammatory tripeptide component of the blend. It is paired with GHK-Cu for dermal fibroblast research, with BPC-157 for localized tissue repair research, and with TB-500 for systemic tissue repair research. The pillar article on the KLOW peptide blend discusses how the proposed pathway interactions across these four peptides may produce research signals that are not observable with single peptide studies.

For research handling, KPV is generally well behaved under standard cold storage conditions due in part to its small size and chemical simplicity. Researchers working with KLOW 90mg should follow good laboratory practice and consult the Certificate of Analysis supplied with the product for peptide identity and purity information.

Open Research Questions

Several open research questions remain in the KPV preclinical literature, despite the consistent body of evidence on its anti-inflammatory activity. These include how KPV uptake through the PEPT1 transporter compares quantitatively across different cell types and tissues, how the intracellular targets of KPV mediate the observed anti-inflammatory effects, and how the combined formulation with other research peptides in blends like KLOW affects the timing and magnitude of inflammatory endpoints in standardized research models. Each of these is a legitimate research opportunity for investigators studying small anti-inflammatory peptides.

Conclusion

KPV peptide research provides a focused and mechanistically distinctive body of preclinical literature on small anti-inflammatory peptides derived from melanocortin biology. The proposed cellular uptake through the PEPT1 transporter, the consistent anti-inflammatory findings across cell culture and animal model studies, and the active research base in intestinal and dermal contexts make KPV a useful research tool. Its inclusion in multi-peptide research formulations like KLOW reflects an interest in studying anti-inflammatory pathways alongside dermal repair and tissue repair processes in research models.

For more on the full KLOW research cluster, see the pillar overview article and the supporting articles on each constituent peptide.

KPV is supplied by Midwest Peptide for research use only and is not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

GHK-Cu 50mg, 99%+ purity, COA included
TB-500 10mg, 99%+ purity, COA included
BPC-157 10mg, 99%+ purity, COA included
KLOW 90mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

KPV Peptide Research: The Anti-Inflammatory Tripeptide and Its Preclinical Literature